The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine

• Published in: Scientific reports Vol. 10; no. 1; pp. 20319 - 12
• Main Authors: Chen, Shan-Ming, Chieng, Wee-Wei, Huang, Szu-Wei, Hsu, Li-Jin, Jan, Ming-Shiou
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.11.2020; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326; 631/67; 692/4020; Adenocarcinoma; Administration, Oral; Alanine; Alanine transaminase; Animals; Antimetabolites, Antineoplastic - administration & dosage; Aspartate aminotransferase; Cancer therapies; Carcinoma, Pancreatic Ductal - chemically induced; Carcinoma, Pancreatic Ductal - diet therapy; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - microbiology; Ceruletide - adverse effects; Chemotherapy; Combined treatment; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease Models, Animal; Female; Gastrointestinal Microbiome - drug effects; Gemcitabine; Humanities and Social Sciences; Injections, Intraperitoneal; Intestinal microflora; Lactobacillus; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbiota; multidisciplinary; Oral administration; Pancreatic cancer; Pancreatic Neoplasms - chemically induced; Pancreatic Neoplasms - diet therapy; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - microbiology; Pancreatitis; Probiotics; Probiotics - administration & dosage; Rodents; Science; Science (multidisciplinary); Transgenic mice; Treatment Outcome; Vimentin

Pancreatic cancer is one of the most lethal and chemo-resistant cancers worldwide. Growing evidence supports the theory that the gut microbiota plays an essential role in modulating the host response to anti-cancer therapy. The present study aimed to explore the effect of probiotics as an adjuvant d...